In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 ...

The following is a summary of "ADORA2B promotes proliferation and migration in head and neck squamous cell carcinoma and is ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...

The warm sunshine of spring is a welcome change from the cold and brutal winds of winter in the Upper Midwest. However, with ...

Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset ...

Donald Trump has suffered a skin cancer scare following his latest medical report after doctors found "benign lesions" ...

New clinical insights support U.S. doctors in using transoral robotic surgery (TORS) to personalize treatment plans for ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

ALX Oncology (ALXO) announced topline data from its Phase 2 ASPEN-03 and ASPEN-04 clinical trials. The company’s investigational CD47-blocker ...

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...